Shire’s Ornskov dictates another big revamp, with R&D/HQ moving into Cambridge
Shire CEO Flemming Ornskov is once again reorganizing the company, consolidating a large portion of the company’s R&D operations in the heart of the big Cambridge, MA hub.
In a story broken by the Boston Globe’s longtime biotech scribe Rob Weisman, Ornskov says he plans to move hundreds of researchers into the company’s new campus in Kendall Square, which combines a newly acquired building from Sanofi Genzyme with the R&D center picked up in its acquisition of Baxalta.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.